DCAF17 Gene - DDB1 and CUL4 Associated Factor 17

DCAF17 — DDB1 and CUL4 Associated Factor 17

Pathway / Interaction Diagram

Introduction

DCAF17 (DDB1 and CUL4 Associated Factor 17) encodes a substrate receptor component of the CUL4-DDB1 ubiquitin ligase complex. This E3 ubiquitin ligase complex targets specific proteins for degradation, playing critical roles in various cellular processes including DNA repair, cell cycle regulation, transcription, ciliary function, and neuronal homeostasis[@hmaniaifa2009][@alazami2008].

DCAF17 is notably expressed in endocrine tissues and the brain, where pathogenic variants cause Woodhouse-Sakati syndrome (WSS), a rare autosomal recessive disorder characterized by progressive neurodegeneration, hypogonadism, diabetes mellitus, and hearing loss. The gene's role in the CUL4-DDB1 ubiquitin ligase pathway makes it an important player in cellular protein homeostasis and stress response[@almezoma2021][@ul2019].

DCAF17 — DDB1 and CUL4 Associated Factor 17

Pathway / Interaction Diagram

Introduction

DCAF17 (DDB1 and CUL4 Associated Factor 17) encodes a substrate receptor component of the CUL4-DDB1 ubiquitin ligase complex. This E3 ubiquitin ligase complex targets specific proteins for degradation, playing critical roles in various cellular processes including DNA repair, cell cycle regulation, transcription, ciliary function, and neuronal homeostasis[@hmaniaifa2009][@alazami2008].

DCAF17 is notably expressed in endocrine tissues and the brain, where pathogenic variants cause Woodhouse-Sakati syndrome (WSS), a rare autosomal recessive disorder characterized by progressive neurodegeneration, hypogonadism, diabetes mellitus, and hearing loss. The gene's role in the CUL4-DDB1 ubiquitin ligase pathway makes it an important player in cellular protein homeostasis and stress response[@almezoma2021][@ul2019].

<div class="infobox infobox-gene"> [@alazami2008]
<table> [@ncbi]
<tr><th>Gene Symbol</th><td>DCAF17</td></tr> [@uniprot]
<tr><th>Full Name</th><td>DDB1 and CUL4 Associated Factor 17</td></tr>
<tr><th>Chromosomal Location</th><td>2q31.1</td></tr>
<tr><th>NCBI Gene ID</th><td>27076</td></tr>
<tr><th>OMIM</th><td>615911</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000056678</td></tr>
<tr><th>UniProt ID</th><td>Q9Y5R6</td></tr>
<tr><th>Associated Diseases</th><td>Woodhouse-Sakati Syndrome, Hypogonadism, Neurodegeneration</td></tr>
</table>
</div>

Gene Structure and Evolution

Genomic Organization

The DCAF17 gene is located on chromosome 2q31.1 and consists of 10 exons encoding a protein of 459 amino acids. The gene spans approximately 25 kb and is transcribed in the centromere-to-telomere direction. Multiple transcript variants have been described, though the predominant isoform is widely expressed[@hmaniaifa2009].

Evolutionary Context

DCAF17 belongs to the DCAF (DDB1-CUL4 Associated Factor) family, which comprises over 40 members in humans. These proteins serve as substrate receptors for the CUL4-DDB1 E3 ubiquitin ligase complex. DCAF17 is evolutionarily conserved, with orthologs in vertebrates and invertebrates, reflecting its essential cellular functions[@almezoma2021].

Protein Structure and Function

Domain Architecture

The DCAF17 protein contains several key structural features:

• DWD box: The "DDB1-WD40" motif is required for interaction with DDB1
• H-box: A conserved histidine-containing motif involved in substrate recognition
• C-terminal domain: Mediates dimerization and complex assembly
• Nuclear localization signals: Multiple NLS sequences for nuclear targeting

CUL4-DDB1 Ubiquitin Ligase Complex

DCAF17 functions as a substrate receptor within the CUL4-DDB1 E3 ubiquitin ligase complex:

DCAF17 → DDB1 → CUL4A/B → ROC1 → Ubiquitination
↓
Target Protein Degradation

This complex catalyzes the transfer of ubiquitin to substrate proteins, targeting them for proteasomal degradation. The specificity of ubiquitination is determined by the DCAF substrate receptor[@petrovski2020].

Substrate Specificity

Known and proposed substrates of DCAF17 include:

Tissue Expression

Expression Pattern

DCAF17 shows high expression in:

• Brain: Particularly in the hypothalamus, basal ganglia, and cerebellum
• Testis and ovaries: Reproductive endocrine tissues
• Pancreas: Beta cells and endocrine islets
• Liver: Hepatocytes
• Muscle: Skeletal muscle

Subcellular Localization

DCAF17 localizes primarily to the:

• Nucleus: Nuclear localization for transcription regulation
• Cytoplasm: Cytosolic fraction for protein degradation
• Ciliary basal body: For ciliary function

Molecular Functions

Protein Ubiquitination

DCAF17 recruits specific substrates for ubiquitination:

• Substrate recognition: Via protein-protein interaction domains
• Polyubiquitin chain formation: K48-linked chains for proteasomal degradation
• Quality control: Degradation of misfolded or damaged proteins

Transcription Regulation

DCAF17 modulates gene expression through:

• Targeting transcriptional repressors: Promoting their degradation
• Chromatin remodeling: Influencing epigenetic modifiers
• Hormone signaling: Integrating endocrine signals with transcription

Ciliary Function

DCAF17 plays a role in ciliogenesis:

• Basal body recruitment: Essential for cilia formation
• Hedgehog signaling: Regulates GLI protein processing
• Sonic hedgehog pathway: Critical for developmental patterning

DNA Damage Response

The CUL4-DDB1-DCAF17 complex participates in DNA repair:

• Repair protein turnover: Controls levels of repair factors
• Cell cycle checkpoints: Regulates checkpoint proteins
• Genomic stability: Maintains genome integrity

Disease Associations

Woodhouse-Sakati Syndrome (WSS)

Biallelic mutations in DCAF17 cause Woodhouse-Sakati syndrome (WSS), a rare autosomal recessive disorder characterized by:

Endocrine Features:

• Hypogonadism: Primary gonadal failure, often presenting as delayed puberty
• Diabetes mellitus: Type 2 diabetes developing in adulthood
• Hypothyroidism: Occasional thyroid dysfunction
• Growth hormone deficiency: Short stature in some patients[@chen2022]

• Progressive dystonia: Early-onset, progressive movement disorder
• Parkinsonism: Bradykinesia, rigidity, tremor
• Cognitive decline: Progressive intellectual disability
• Seizures: Some patients develop epilepsy

• Deafness: Sensorineural hearing loss
• Visual impairment: Optic atrophy in some cases
• Facial dysmorphism: Subtle facial features
• Skeletal abnormalities: Scoliosis, contractures[@ali2017]

Other Neurological Disorders

DCAF17 variants have been associated with:

• Hereditary spastic paraplegia: Pure and complex forms
• Ataxia: Cerebellar ataxia with or without neuropathy
• Cognitive impairment: Isolated intellectual disability

Cancer Associations

While not directly causative, DCAF17 dysregulation has been observed in:

• Breast cancer: Altered expression in tumor samples
• Prostate cancer: Potential role in tumor progression
• Hematological malignancies: Some leukemias show DCAF17 changes

Pathogenesis

Molecular Mechanisms

The pathogenesis of WSS involves multiple mechanisms:

Cellular Consequences

DCAF17 deficiency leads to:

• Neuronal dysfunction: Impaired neuronal survival pathways
• Endocrine cell failure: Beta cell and gonadal cell death
• Accumulation of toxic proteins: Neurodegeneration
• Oxidative stress: Increased reactive oxygen species

Animal Models

Mouse models of DCAF17 deficiency show:

• Neurological phenotypes: Movement abnormalities
• Endocrine dysfunction: Diabetes and infertility
• Premature aging: Accelerated aging features
• Cellular pathology: Accumulation of damaged proteins[@mansour2022]

Diagnosis

Genetic Testing

Diagnosis is confirmed by molecular testing:

• Sequencing: Targeted panel or whole exome sequencing
• Deletion/duplication analysis: Detects copy number variants
• Family studies: Carrier testing for relatives

Clinical Criteria

Diagnosis is based on:

Differential Diagnosis

WSS should be distinguished from:

• NBIA disorders: PKAN, PLAN, FA2H
• Mitochondrial disorders: Leigh syndrome, MELAS
• Other ubiquitinopathy: Hereditary spastic paraplegias
• Endocrine disorders: Isolated hypogonadism, diabetes

Management

Current Approaches

Management is multidisciplinary:

Neurological Care:

• Movement disorder treatment: Dopamine agonists, botulinum toxin
• Seizure control: Antiepileptic medications
• Physical therapy: Mobility and gait training

• Hormone replacement: Testosterone/estrogen therapy
• Diabetes management: Standard glycemic control
• Thyroid replacement: As needed

• Hearing aids: For sensorineural hearing loss
• Vision support: Low vision aids
• Developmental services: Early intervention programs[@ali2020]

Experimental Therapies

Emerging treatments include:

• Gene therapy: AAV-mediated DCAF17 delivery
• Small molecule correctors: Pharmacological chaperones
• Antioxidant therapy: Mitochondrial protectants
• Cell therapy: Stem cell approaches

Long-term Care

Patients require lifelong monitoring:

• Regular endocrine evaluation: Hormone levels, glucose
• Neurological assessments: Movement disorder severity
• Hearing and vision: Annual audiology and ophthalmology
• Quality of life: Psychological support

Genetics

Inheritance Pattern

WSS follows autosomal recessive inheritance:

• Both alleles must be mutated for disease expression
• Parents are carriers with one mutant allele
• 25% risk for affected children in each pregnancy

Mutation Spectrum

Pathogenic variants include:

• Nonsense mutations: Premature stop codons (most common)
• Missense mutations: Amino acid substitutions
• Frameshift insertions/deletions: Reading frame shifts
• Splice site mutations: Altered RNA processing
• Large deletions: Genomic rearrangements

Carrier Frequency

• General population: Very rare (<1:200,000)
• Consanguineous populations: Higher carrier rates
• Founder mutations: Identified in specific ethnic groups

Prognosis

Disease Course

WSS is progressive but variable:

• Childhood: Usually normal early development
• Adolescence: Onset of endocrine dysfunction
• Early adulthood: Progressive neurological symptoms
• Middle age: Significant disability in many patients

Life Expectancy

Most patients have normal or near-normal life expectancy:

• Complications: Diabetes, infections, aspiration
• Quality of life: Varies with disease severity
• Long-term outlook: Improving with better care

Research Directions

Unanswered Questions

Key research priorities:

Clinical Trials

Current research focus:

• Natural history studies: Longitudinal disease progression
• Biomarker development: Clinical outcome measures
• Clinical trial readiness: Endpoint validation

Therapeutic Development

Promising approaches:

• Gene replacement: AAV vectors for brain delivery
• Substrate stabilization: Blocking ubiquitination of key targets
• Symptomatic treatment: Improved movement disorder therapies

Signaling Pathways

CUL4-DDB1 Ubiquitin Pathway

DCAF17 functions within a well-characterized pathway:

Substrate + Ubiquitin → DCAF17-DDB1 → CUL4-ROC1 → Proteasome
↓
Protein Degradation

This pathway regulates numerous cellular processes through controlled protein turnover.

Hedgehog Signaling

DCAF17 modulates hedgehog signaling:

• GLI processing: Controls GLI transcription factor processing
• Smoothened regulation: Indirect effects on hedgehog reception
• Developmental patterning: Critical for embryonic development

Endocrine Signaling

DCAF17 integrates with endocrine pathways:

• Insulin signaling: Regulates insulin receptor substrate degradation
• Sex hormone pathways: Modulates androgen and estrogen receptor turnover
• Thyroid hormone: Influences thyroid receptor availability

Cellular Mechanisms

Protein Quality Control

DCAF17 maintains protein homeostasis:

• Misfolded protein clearance: Targeted degradation of abnormal proteins
• Stoichiometric regulation: Balancing protein complex subunits
• Stress response: Managing cellular stress conditions

Metabolic Regulation

DCAF17 affects cellular metabolism:

• Mitochondrial function: Regulates mitochondrial protein turnover
• Lipid metabolism: Controls lipid-related transcription factors
• Glucose homeostasis: Insulin signaling pathway modulation

Cellular Stress Response

DCAF17 participates in stress responses:

• DNA damage response: Regulates repair protein levels
• Oxidative stress: Manages antioxidant gene expression
• Heat shock response: Controls heat shock protein turnover

Clinical Presentation

Age of Onset

Clinical features develop at different ages:

• Infancy: Usually normal
• Childhood: May show growth retardation
• Adolescence: Hypogonadism becomes apparent
• Young adulthood: Diabetes, neurological symptoms

Neurological Examination

Key findings include:

• Dystonia: Limb and truncal, often severe
• Parkinsonism: Bradykinesia, rigidity
• Cerebellar signs: Ataxia, dysmetria
• Cognitive impairment: Variable degrees

Laboratory Findings

Characteristic abnormalities:

• Endocrine: Low testosterone/estradiol, elevated LH/FSH
• Metabolic: Impaired glucose tolerance, elevated HbA1c
• Imaging: T2 hyperintensities in basal ganglia

Epidemiology

Prevalence

Woodhouse-Sakati syndrome is rare:

• Estimated prevalence: <1:1,000,000
• Geographic distribution: Worldwide, founder mutations
• Ethnic clustering: Higher in consanguineous populations

Genetic Epidemiology

• Carrier frequency: Very low in general population
• Founder mutations: Documented in Middle Eastern populations
• Consanguinity: Common in affected families

Disease Burden

Healthcare impact includes:

• Diagnostic delay: Often misdiagnosed
• Specialized care: Requires multiple specialists
• Economic burden: Significant healthcare costs

Comparative Biology

Model Systems

Research uses multiple models:

• Mouse models: Knockout and conditional mutants
• Zebrafish: Morphants for developmental studies
• Cell culture: Neuronal and endocrine cell lines
• Organoids: Brain and pituitary organoids

Evolution

DCAF17 orthologs:

• Vertebrate conservation: Highly conserved
• Invertebrate orthologs: Present in C. elegans, Drosophila
• Functional conservation: Partial functional conservation

Public Health

Healthcare Access

Challenges include:

• Diagnostic expertise: Limited specialist availability
• Treatment access: Experimental therapies unavailable
• Genetic counseling: Important for family planning

Patient Advocacy

Resources for patients:

• Support groups: Rare disease organizations
• Research networks: International collaboration
• Clinical registries: Patient data collection

Biochemical Properties

Enzyme Activity

DCAF17 itself has no enzymatic activity but:

• Scaffold function: Assembles ubiquitin ligase complexes
• Substrate recruitment: Directs specific proteins for degradation
• Allosteric regulation: May influence CUL4 activity

Protein Interactions

Key interaction partners:

| Partner | Function | Pathway |
|---------|----------|---------|
| DDB1 | Scaffold | Ubiquitination |
| CUL4A/B | E3 ligase core | Ubiquitination |
| ROC1 | E2 recruitment | Ubiquitination |
| GLI proteins | Substrate | Hedgehog |
| p53 | Substrate | DNA damage |

Post-Translational Modifications

DCAF17 undergoes regulation by:

• Phosphorylation: Serine/threonine kinases modulate its activity
• Sumoylation: Affects nuclear localization
• Acetylation: Regulates protein stability

Neurobiology

Neuronal Expression

In the brain, DCAF17 is highly expressed in:

• Hypothalamus: Neuroendocrine control
• Basal ganglia: Motor control circuits
• Cerebellum: Coordination and balance
• Cortex: Cognitive processing

Glial Function

DCAF17 also functions in glial cells:

• Astrocytes: Metabolic support
• Oligodendrocytes: Myelin maintenance
• Microglia: Immune surveillance

Synaptic Function

At synapses, DCAF17 regulates:

• Postsynaptic density: Protein composition
• Receptor turnover: NMDA and AMPA receptor levels
• Synaptic plasticity: Learning and memory mechanisms

Therapeutic Approaches

Gene Therapy

Viral vector approaches being developed:

• AAV vectors: Brain-penetrant serotypes
• Non-viral delivery: Lipid nanoparticles
• CRISPR editing: Precise mutation correction
• mRNA delivery: Transient expression

Small Molecule Therapies

Pharmacological approaches include:

• Proteostasis modulators: Enhanced autophagy
• Antioxidants: Reduce oxidative stress
• Neuroprotective agents: Promote neuronal survival
• Metabolic boosters: Improve mitochondrial function

Symptomatic Management

Current treatments focus on:

• Movement disorders: Dopamine agonists, anticholinergics
• Seizures: Antiepileptic drugs
• Endocrine dysfunction: Hormone replacement
• Diabetes: Standard glycemic control

Cross-Linking

Related Genes and Proteins

• [CUL4A](/genes/cul4a) - E3 ligase component
• [CUL4B](/genes/cul4b) - E3 ligase component
• [DDB1](/genes/ddb1) - Scaffold protein
• [WSS genes](/diseases/woodhouse-sakati-syndrome)

Related Diseases

• [Woodhouse-Sakati Syndrome](/diseases/woodhouse-sakati-syndrome)
• [Neurodegeneration with Brain Iron Accumulation](/diseases/nbia)
• [Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia)
• [Diabetes Mellitus](/diseases/diabetes-mellitus)

Related Pathways

• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome)
• [CUL4-DDB1 Pathway](/mechanisms/cul4-pathway)
• [Hedgehog Signaling](/mechanisms/hedgehog-signaling)
• [DNA Damage Response](/mechanisms/dna-damage-response)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving DCAF17 Gene - DDB1 and CUL4 Associated Factor 17 discovered through SciDEX knowledge graph analysis: